AstraZeneca to buy Acerta for blood cancer drug


AstraZeneca has agreed to buy a majority stake in Acerta Pharma, a privately-owned biopharmaceutical company based in the Netherlands and US.

The deal gives AstraZeneca access to Acerta’s acalabrutinib, a Bruton’s tyrosine kinase (BTK) inhibitor, which is currently in clinical trials. ‘We are boosting a key area in our comprehensive oncology portfolio with a late-stage, potential best-in-class medicine that could transform treatment for patients across a range of blood cancers,’ AstraZeneca's chief executive Pascal Soriot said in a statement.

AstraZeneca will pay $2.5 billion (£1.7 billion) up-front for a 55% share of Acerta, followed by $1.5 billion when acalabrutinib is first approved in the US, or at the end of 2018, whichever is sooner.


Related Content

Pharma queues up for checkpoint inhibitor collaborations

3 July 2015 Business

news image

Combinations of different firms’ drugs seek to reap immuno-oncology’s benefits

Clinical collaborations drive cancer immunotherapy

27 August 2014 Business

news image

Companies race to pair up chemotherapy drugs with immune system-boosting antibodies to greatest effect in trials

Most Commented

Sweet tear sensor could ease pain of diabetes

29 June 2016 Research

news image

New non-invasive sensor could check blood glucose levels using tears

The sultan of synthesis

11 April 2014 Feature

news image

Phil Baran is spurring organic chemists to rethink how they make complex compounds, as Mark Peplow discovers